Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online January 13, 2005.
Copyright & Usage
THE JOURNAL OF NUCLEAR MEDICINE
Author Information
- Dik J. Kwekkeboom, MD1,
- Jan Mueller-Brand, MD2,
- Giovanni Paganelli, MD3,
- Lowell B. Anthony, MD4,
- Stanislas Pauwels, MD5,
- Larry K. Kvols, MD6,
- Thomas M. O’Dorisio, MD7,
- Roelf Valkema, MD1,
- Lisa Bodei, MD3,
- Marco Chinol, PhD3,
- Helmut R. Maecke, PhD2 and
- Eric P. Krenning, MD1
- 1Department of Nuclear Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands
- 2Department of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
- 3Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy
- 4Division of Hematology and Oncology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana
- 5Department of Nuclear Medicine, Universitaire Catholique Louvain, Brussels, Belgium
- 6Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida
- 7Division of Endocrinology, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors
- Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine
- A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting
- Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
- Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
- Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours
- Study of the Impact of Tissue Density Heterogeneities on 3-Dimensional Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct Monte Carlo Methods
- Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- Altered Biodistribution of Somatostatin Analogues After First Cycle of Peptide Receptor Radionuclide Therapy
- Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors
- Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
- High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids
- Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules
- Tumor Receptor Imaging
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
- Renal Uptake of Radiolabeled Octreotide in Human Subjects Is Efficiently Inhibited by Succinylated Gelatin
- Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
- Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship
- Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate